Interim efficacy and preliminary survival outcomes of polatuzumab vedotin in combination for diffuse large B-cell lymphoma: a retrospective real-world study. (PubMed, Front Oncol) - Sep 20, 2026 - "The standard first-line R-CHOP regimen achieves cure in only approximately 50% of patients. Six-month PFS rates were 90.4% (95% CI: 84.8%-96.3%) for the Pola group and 76.9% (95% CI: 62.3%-94.9%) for the non-Pola group, while 12-month PFS rates were 87.2% (95% CI: 80.5%-94.6%) and 67.9% (95% CI: 51.7%-89.2%), respectively. Combination regimens containing Polatuzumab vedotin demonstrated a marked interim efficacy advantage, which may translate into potential long-term survival benefits."
Journal • Real-world evidence • Retrospective data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin's Lymphoma • Oncology • CD79B
|
|
Hong Xu; Lingjie Sun; Songshen Liu; Wei Wang; Xia Zhao; Xue Shi
|